Fig. 3
Analysis of A549 lung tumors and HCT116 colon tumors under combinatorial treatment. a and c A549 (a) and HCT116 (c) tumor volume measured by caliper in mice treated for 14 days with vehicle (CTR 
), or BKM120 ( 
), or CB-839 ( 
), or a combination of BKM120 plus CB-839 ( 
). b and d Kaplan–Meier survival curves of A549 lung (b) and HCT116 colon (d) tumor-bearing mice. The combined treatment significantly increases survival, as compared with BKM120 alone (p < 0.05). e, f Evaluation of hepatotoxic effects of drugs by assessing aspartate transaminase (GOT) and alanine transaminase (GPT) on the liver from A549 (e) and HCT116 (f) tumor-bearing mice exposed to the combinatorial treatment compared to CTR. g, h Representative transaxial [18F]FDG PET images of A549 (g) and HCT116 (h) tumors in CTR and combined-treatment mice performed before and after drug administration for 1 or 2 weeks. The color scale is expressed as Standardized Uptake Value. i and k [18F]-FDG uptake in A549 (i) and HCT116 (k) tumors exposed to the combined treatment (Treat) compared with CTR, expressed as tumor to background ratio (T/B). j and l Lactate labeling evaluated by [U-13C6]Glc infusion in A549 (j) and HCT116 (l) xenograft mice exposed to the combined treatment compared to CTR and analyzed by GC-MS. m and o GSSG/GSH ratio in CTR ( 
) or combined treatment ( 
) in A549 (M) and HCT116 (o) xenografts based on relative abundance obtained by LC-MS analysis. n and p NADH/NAD+ ratio in CTR ( 
) or combined treatment ( 
) in A549 (N) and HCT116 (P) xenografts based on relative abundance obtained by LC-MS analysis. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001